Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 1.00 |
| ▸ | RAB9A | P51151 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.76 |
| ▸ | GAA | P10253 | 4/20 | 0.76 |
| ▸ | GLA | P06280 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.63 |
| ▸ | TUBB | P07437 | 6/20 | 0.63 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.63 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.63 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660212 | 1.00 | NPC1 (1.00) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL537905 | 1.00 | NPC1 (1.00) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL31305038 | 0.94 | NPC1 (0.89) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL1086983 | 0.90 | ALDH1A1 (0.81) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL1086985 | 0.90 | ALDH1A1 (0.81) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL29539476 | 0.90 | ALDH1A1 (0.81) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL709083 | 0.90 | NPC1 (0.81) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL709082 | 0.90 | NPC1 (0.81) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL5572505 | 0.86 | NPC1 (0.76) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL6481418 | 0.86 | NPC1 (0.76) | NPC1RAB9AKMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108653281-B | Application of E-2-styryl benzimidazole compound in preparation of anti-hepatitis B virus drugs | 中山大学 | 2020-06-09 | — | — | CN | claimed |
| US-20100256378-A1 | FLUORESCENT CELLULAR MARKERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-10-07 | — | — | US | claimed |
| EP-0830345-A1 | STYRYL BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-25 | — | — | EP | claimed |
| WO-1996039391-A1 | STYRYL BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-12-12 | — | — | WO | claimed |
| JP-6173023-A | — | — | None | — | — | JP | disclosed |
| US-12024732-B2 | Method for preparing nitrogen-containing heterocyclic compound and derivative thereof by enzymatic-chemical cascade method | NANJING TECH UNIVERSITY (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12024732-B2 | Method for preparing nitrogen-containing heterocyclic compound and derivative thereof by enzymatic-chemical cascade method | NANJING TECH UNIVERSITY (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20240026400-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND DERIVATIVE THEREOF BY ENZYMATIC-CHEMICAL CASCADE METHOD | NANJING TECH UNIVERSITY (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240026400-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND DERIVATIVE THEREOF BY ENZYMATIC-CHEMICAL CASCADE METHOD | NANJING TECH UNIVERSITY (CN) | 2024-01-25 | — | — | US | disclosed |
| CN-108653281-B | Application of E-2-styryl benzimidazole compound in preparation of anti-hepatitis B virus drugs | 中山大学 | 2020-06-09 | — | — | CN | disclosed |
| CN-108503648-B | Styryl pyrazolopyrimidine compound, pharmaceutical composition, preparation method and application | 安徽医科大学 | 2020-04-14 | — | — | CN | disclosed |
| US-20190145981-A1 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | SPHINGOTEC THERAPEUTICS GMBH (DE) | 2019-05-16 | — | — | US | disclosed |
| US-5880076-A | PERSONAL PRODUCT OR DETERGENT COMPOSITION COMPRISING CYCLIC GLYCACARBAMATE AND/OR GLYCAUREA, SURFACTANT | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5795409-A | MIXTURE OF A (BENZ)IMIDAZOLE COMPOUND, CHELATE COMPOUND AND IRON | SHIKOKU CHEMICALS CORPORATION (JP) | 1998-08-18 | — | — | US | disclosed |
| EP-0830345-A1 | STYRYL BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-25 | — | — | EP | disclosed |
| EP-0791671-A1 | Surface treating agent for copper or copper alloy | SHIKOKU CHEMICALS CORPORATION (JP) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996039391-A1 | STYRYL BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0550634-B1 | POLYHYDROXY FATTY ACID AMIDES IN BRIGHTENER-CONTAINING LIQUID DETERGENT COMPOSITIONS | PROCTER & GAMBLE (US) | 1994-08-03 | — | — | EP | disclosed |
| JP-H06173023-A | SURFACE TREATING AGENT FOR COPPER AND COPPER ALLOY | SHIKOKU CHEM CORP | 1994-06-21 | — | — | JP | disclosed |
| US-5174927-A | Detergent and builders | THE PROCTER & GAMBLE COMPANY (US) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256378-A1 | FLUORESCENT CELLULAR MARKERS | AIFM1, CASP3, BAX | NPC1 1894/4885RAB9A 862/4885KMT2A 1656/4885 |
| US-20190145981-A1 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | DPP3, DPP4, DPP7 | NPC1 1090/4885RAB9A 3054/4885KMT2A 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.